January 2022 in “Galicia Clínica” Alopecia universalis can be an early sign of HIV.
6 citations,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
97 citations,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
34 citations,
April 2009 in “Expert Opinion on Pharmacotherapy” Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.
13 citations,
April 2016 in “Journal of Dermatology” 308-nm excimer light therapy helped over a third of treatment-resistant alopecia universalis patients regrow most of their hair.
January 2017 in “Journal of cosmetology & trichology” A man with severe hair loss regrew hair after hormone treatment.
1 citations,
April 2019 in “Acta Medica Philippina” Azathioprine may help treat severe alopecia areata, but more research is needed.
1 citations,
September 2022 in “JMIR dermatology” Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.
56 citations,
January 2019 in “Skin appendage disorders” The most common hair loss type at specialist clinics is androgenetic alopecia, especially in younger men, followed by alopecia areata and telogen effluvium, with differences seen across regions.
35 citations,
May 2012 in “Expert Opinion on Pharmacotherapy” The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
30 citations,
September 2017 in “Clinics in Dermatology” Men with common hair loss may have a higher risk of heart disease and diabetes, and should be checked for these conditions.
14 citations,
December 2010 in “Dermatologica Sinica” New treatments for hair loss show promise, but more development is needed, especially for tough cases.
11 citations,
November 2021 in “BMJ Open” People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
March 2021 in “Actas Dermo-Sifiliográficas” The microbiome may be linked to hair loss and could be a target for new treatments.
2 citations,
December 2007 in “Expert Review of Dermatology” The document concludes that early diagnosis and treatment are key for pediatric hair loss disorders, and addressing the emotional effects on children is important.
24 citations,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
11 citations,
October 2021 in “Stem Cell Research & Therapy” Hair follicle stem cells reduced hair loss and inflammation in mice with a condition similar to human alopecia.
September 2023 in “JEADV Clinical Practice” People with common hair loss conditions may have a higher risk of heart disease and related health issues.
10 citations,
January 2012 in “Case reports in medicine” Diphencyprone can cause unexpected and possibly permanent vitiligo.
April 2022 in “Research Square (Research Square)” The combination of laser and topical steroids is more effective for treating alopecia areata than topical steroids alone.
2 citations,
January 2012 in “Hair therapy & transplantation” Low serum ferritin levels are not closely linked to telogen effluvium in women.
December 2023 in “International journal of multidisciplinary research and analysis” SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.
25 citations,
July 2019 in “Experimental Dermatology” Cholesterol balance is important for hair health, and problems with it can lead to hair loss conditions.
36 citations,
May 2005 in “BMC dermatology” DPCP is effective for treating severe alopecia areata, but relapse is common.
87 citations,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
41 citations,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
18 citations,
January 2013 in “PLoS ONE” HLA-DRB5 and other genes may be linked to alopecia universalis.
9 citations,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
4 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.